Interplay of β-catenin with xenobiotic-sensing receptors and its role in glutathione S-transferase expression

Current Drug Metabolism

Volumn 13, Issue 2, 2012, Pages 203-214

  Braeuning, Albert ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

catenin; Aryl hydrocarbon receptor; Constitutive androstane receptor; Drug metabolism; Liver tumor; Metabolic zonation; Phase II; Wnt signaling

Indexed keywords

BETA CATENIN; CONSTITUTIVE ANDROSTANE RECEPTOR; GLUTATHIONE TRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR PXR; UNCLASSIFIED DRUG; WNT PROTEIN; XENOBIOTIC SENSING RECEPTOR;

ARTICLE; DRUG METABOLISM; HUMAN; LIVER ADENOMA; MASS SPECTROMETRY; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; GLUTATHIONE TRANSFERASE; HUMANS; LIVER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; WNT PROTEINS; XENOBIOTICS;

EID: 84857564987     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012798918381     Document Type: Article

References (116)

1. Behari, J. The Wnt/beta-catenin signaling pathway in liver biology and disease. Expert Rev. Gastroenterol. Hepatol., 2010, 4, 745-756.
2. Thompson, M.D.; Monga, S.P. WNT/beta-catenin signaling in liver health and disease. Hepatology, 2007, 45, 1298-1305. (Pubitemid 46775794)
3. Gebhardt, R; Hovhannisyan, A. Organ patterning in the adult stage: The role of Wnt/beta-catenin signaling in liver zonation and beyond. Dev. Dyn., 2010, 239, 45-55.
4. Torre, C.; Perret, C.; Colnot, S. Transcription dynamics in a physiological process: Beta-Catenin signaling directs liver metabolic zonation. Int. J. Biochem. Cell Biol., 2011, 43, 271-278.
5. Behrens, J.; Lustig, B. The Wnt connection to tumorigenesis. Int. J. Dev. Biol., 2004, 48, 477-487. (Pubitemid 39360398)
6. Lustig, B.; Behrens, J. The Wnt signaling pathway and its role in tumor development. J. Cancer Res. Clin. Oncol., 2003, 129, 199-221. (Pubitemid 36713796)
7. Takigawa, Y.; Brown, A.M. Wnt signaling in liver cancer. Curr. Drug Targets, 2008, 9, 1013-1024.
8. Whittaker, S.; Marais, R.; Zhu, A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010, 29, 4989-5005.
9. Cavard, C.; Colnot, S.; Audard, V.; Benhamouche, S.; Finzi, L.; Torre, C.; Grimber, G.; Godard, C.; Terris, B.; Perret, C. Wnt/betacatenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol., 2008, 4, 647-660.
10. MacDonald, B.T.; Tamai, K.; He, X. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev. Cell, 2009, 17, 9-26.
11. van Noort, M.; Clevers, H. TCF transcription factors, mediators of Wnt-signaling in development and cancer. Dev. Biol., 2002, 244, 1-8. (Pubitemid 34271136)
12. Willert, K.; Nusse, R. Beta-catenin: A key mediator of Wnt signaling. Curr. Opin. Genet. Dev., 1998, 8, 95-102. (Pubitemid 28122147)
13. Sekine, S.; Lan, B.Y.A.; Bedolli, M.; Feng, S.; Hebrok, M. Liverspecific loss of β-catenin blocks glutamine synthetis pathway activity and cytochrome P450 expression in mice. Hepatology, 2006, 43, 817-825.
14. Benhamouche, S.; Decaens, T.; Godard, C.; Chambrey, R.; Rickman, D.S.; Moinard, C.; Vasseur-Cognet, M.; Kuo, C.J.; Kahn, A.; Perret, C.; Colnot, S. Apc tumor suppressor gene is the "zonationkeeper" of mouse liver. Dev. Cell, 2006, 10, 759-770. (Pubitemid 43796151)
15. Hailfinger, S.; Jaworski, M.; Braeuning, A.; Buchmann, A.; Schwarz, M. Zonal gene expression in murine liver: Lessons from tumors. Hepatology, 2006, 43, 407-414.
16. Oinonen, T.; Lindros, K.O. Zonation of hepatic cytochrome P-450 expression and regulation. Biochem. J., 1998, 329, 17-35. (Pubitemid 28022286)
17. Lindros, K.O. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Gen. Pharmacol., 1997, 28, 191-196. (Pubitemid 27016124)
18. Gebhardt, R. Metabolic zonation of the liver: Regulation and implications for liver function. Pharmacol. Ther., 1992, 53, 275-354.
19. Tan, X.; Behari, J.; Cieply, B.; Michalopoulos, G.K.; Monga, S.P. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology, 2006, 131, 1561-1572. (Pubitemid 44708943)
20. Braeuning, A.; Ittrich, C.; Kohle, C.; Buchmann, A.; Schwarz, M. Zonal gene expression in mouse liver resembles expression patterns of Ha-ras and beta-catenin mutated hepatomas. Drug Metab. Dispos., 2007, 35, 503-507. (Pubitemid 46513275)
21. Braeuning, A.; Sanna, R.; Huelsken, J.; Schwarz, M. Inducibility of Drug-metabolizing Enzymes by Xenobiotics in Mice with Liverspecific Knockout of Ctnnb1. Drug Metab. Dispos., 2009, 37, 1138-1145.
22. Braeuning, A. Regulation of cytochrome p450 expression by rasand Beta catenin-dependent signaling. Curr. Drug Metab., 2009, 10, 138-158.
23. Braeuning, A.; Schwarz, M. beta-Catenin as a Multilayer Modulator of Zonal Cytochrome P450 Expression in Mouse Liver. Biol. Chem., 2010, 391, 139-148.
24. Colletti, M.; Cicchini, C.; Conigliaro, A.; Santangelo, L.; Alonzi, T.; Pasquini, E.; Tripodi, M.; Amicone, L. Convergence of Wnt signaling on the HNF4alpha-driven transcription in controlling liver zonation. Gastroenterology, 2009, 137, 660-672.
25. Rignall, B.; Braeuning, A.; Buchmann, A.; Schwarz, M. Tumor Formation in Liver of Conditional beta-Catenin-Deficient Mice Exposed to a Diethylnitrosamine /Phenobarbital Tumor Promotion Regimen. Carcinogenesis, 2011, 32, 52-57.
26. Hayes, J.D.; Flanagan, J.U.; Jowsey, I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 51-88. (Pubitemid 40261798)
27. Awasthi, Y.C. Toxicology of Glutathione Transferases; CRC Press: Boca Raton, 2006.
28. Di Pietro, G.; Magno, L.A.; Rios-Santos, F. Glutathione Stransferases: An overview in cancer research. Expert Opin. Drug Metab. Toxicol., 2010, 6, 153-170.
29. Kera, Y.; Sippel, H.W.; Penttila, K.E.; Lindros, K.O. Acinar distribution of glutathione-dependent detoxifying enzymes. Low glutathione peroxidase activity in perivenous hepatocytes. Biochem. Pharmacol., 1987, 36, 2003-2006. (Pubitemid 17100223)
30. Suolinna, E.M.; Penttila, K.E.; Winell, B.M.; Sjoholm, A.C.; Lindros, K.O. Drug metabolism by periportal and perivenous rat hepatocytes. Comparison of phase I and phase II reactions and their inducibility during culture. Biochem. Pharmacol., 1989, 38, 1329-1334. (Pubitemid 19101963)
31. Lindros, K.O.; Oinonen, T.; Kettunen, E.; Sippel, H., Muro-Lupori, C.; Koivusalo, M. Aryl hydrocarbon receptor-Associated genes in rat liver: Regional coinduction of aldehyde dehydrogenase 3 and glutathione transferase Ya. Biochem. Pharmacol., 1998, 55, 413-421.
32. Sippel, H.; Lindros, K.O.; Oinonen, T. Distribution of glutathione S-transferase isoforms in rat liver after induction by betanaphthoflavone or 3-methylcholanthrene. Pharmacol. Toxicol., 1996, 79, 80-86. (Pubitemid 26276669)
33. Sippel, H.; Penttila, K.E.; Lindros, K.O. Regioselective induction of liver glutathione transferase by ethanol and acetone. Pharmacol. Toxicol., 1991, 68, 391-393.
34. Selim, N.; Branum, G.D.; Liu, X.; Whalen, R.; Boyer, T.D. Differential lobular induction in rat liver of glutathione S-transferase A1/A2 by phenobarbital. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 278, G542-550. (Pubitemid 30213119)
35. Vanhaecke, T.; Elaut, G.; Rogiers, V. Effect of oxygen concentration on the expression of glutathione S-transferase activity in periportal and perivenous rat hepatocyte cultures. Toxicol. In Vitro, 2001, 15, 387-392. (Pubitemid 32889663)
36. Giera, S.; Braeuning, A.; Kohle, C.; Bursch, W.; Metzger, U.; Buchmann, A.; Schwarz, M. Wnt/beta-catenin signaling activates and determines hepatic zonal expression of glutathione Stransferases in mouse liver. Toxicol. Sci., 2010, 115, 22-33.
37. Stahl, S.; Ittrich, C.; Marx-Stoelting, P.; Kohle, C.; Altug-Teber, O.; Riess, O.; Bonin, M.; Jobst, J.; Kaiser, S.; Buchmann, A.; Schwarz, M. Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology, 2005, 42, 353-361. (Pubitemid 41061088)
38. Strathmann, J.; Paal, K.; Ittrich, C.; Krause, E.; Appel, K.E.; Glauert, H.P.; Buchmann, A.; Schwarz, M. Proteome analysis of chemically induced mouse liver tumors with different genotype. Proteomics, 2007, 7, 3318-3331. (Pubitemid 47517947)
39. Miyoshi, H.; Deguchi, A.; Nakau, M.; Kojima, Y.; Mori, A.; Oshima, M.; Aoki, M.; Taketo, M.M. Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1+/-mice. Cancer Sci., 2009, 100, 2046-2053.
40. Jaworski, M.; Ittrich, C.; Hailfinger, S.; Bonin, M.; Buchmann, A.; Schwarz, M.; Kohle, C. Global gene expression in Ha-ras and B-raf mutated mouse liver tumors. Int. J. Cancer, 2007, 121, 1382-1385. (Pubitemid 47293809)
41. Rignall, B.; Ittrich, C.; Krause, E.; Appel, K.E.; Buchmann, A.; Schwarz, M. Comparative transcriptome and proteome analysis of Ha-ras and B-raf mutated mouse liver tumors. J. Proteome Res., 2009, 8, 3987-3994.
42. Gebhardt, R.; Mecke, D. Heterogeneous distribution of glutamine synthetase among rat liver parenchymal cells in situ and in primary culture. Embo J., 1983, 2, 567-570.
43. Gebhardt, R.; Baldysiak-Figiel, A.; Krugel, V.; Ueberham, E.; Gaunitz, F. Hepatocellular expression of glutamine synthetase: An indicator of morphogen actions as master regulators of zonation in adult liver. Prog. Histochem. Cytochem., 2007, 41, 201-266. (Pubitemid 46412421)
44. Loeppen, S.; Schneider, D.; Gaunitz, F.; Gebhardt, R.; Kurek, R.; Buchmann, A.; Schwarz, M. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse livertumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res., 2002, 62, 5685-5688. (Pubitemid 35204722)
45. Cadoret, A.; Ovejero, C.; Terris, B.; Souil, E.; Levy, L.; Lamers, W.H.; Kitajewski, J.; Kahn, A.; Perret, C. New targets of betacatenin signaling in the liver are involved in the glutamine metabolism. Oncogene, 2002, 21, 8293-8301. (Pubitemid 35477869)
46. Strathmann, J.; Schwarz, M.; Tharappel, J.C.; Glauert, H.P.; Spear, B.T.; Robertson, L.W.; Appel, K.E.; Buchmann, A. PCB 153, a non-dioxin-like Tumor Promoter, Selects for beta-Catenin (Catnb) Mutated Mouse Liver Tumors. Toxicol. Sci., 2006, 93, 34-40. (Pubitemid 44288247)
47. Aydinlik, H.; Nguyen, T.D.; Moennikes, O.; Buchmann, A.; Schwarz, M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene, 2001, 20, 7812-7816. (Pubitemid 33121956)
48. Stahl, S.; Ittrich, C.; Marx-Stoelting, P.; Kohle, C.; Altug-Teber, O.; Riess, O.; Bonin, M.; Jobst, J.; Kaiser, S.; Buchmann, A.; Schwarz, M. Effect of the tumor promoter phenobarbital on the pattern of global gene expression in liver of connexin32-wild-type and connexin32-deficient mice. Int. J. Cancer, 2005, 115, 861-869. (Pubitemid 40791825)
49. Kakizaki, S.; Yamazaki, Y.; Takizawa, D.; Negishi, M. New insights on the xenobiotic-sensing nuclear receptors in liver diseases-CAR and PXR. Curr. Drug Metab., 2008, 9, 614-621.
50. Urquhart, B.L.; Tirona, R.G.; Kim, R.B. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. J. Clin. Pharmacol., 2007, 47, 566-578. (Pubitemid 46632158)
51. Bursch, W.; Chabicovsky, M.; Wastl, U.; Grasl-Kraupp, B.; Bukowska, K.; Taper, H.; Schulte-Hermann, R. Apoptosis in stages of mouse hepatocarcinogenesis: Failure to counterbalance cell proliferation and to account for strain differences in tumor susceptibility. Toxicol. Sci., 2005, 85, 515-529. (Pubitemid 40614281)
52. Markowitz, G.J.; Kadam, S.D.; Boothe, D.M.; Irving, N.D.; Comi, A.M. The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. Neuroreport, 2010, 21, 452-456.
53. Braeuning, A.; Schwarz, M. Zonation of heme synthesis enzymes in mouse liver and their regulation by beta-catenin and Ha-ras. Biol Chem., 2010, 391, 1305-1313.
54. Braeuning, A.; Kohle, C.; Buchmann, A.; Schwarz, M. Coordinate Regulation of Cytochrome P450 1A1 Expression in Mouse Liver by the Aryl Hydrocarbon Receptor and the beta-Catenin Pathway. Toxicol. Sci., 2011, 122, 16-25.
55. Braeuning, A.; Singh, Y.; Rignall, B.; Buchmann, A.; Hammad, S.; Othman, A.; von Recklinghausen, I.; Godoy, P.; Hoehme, S.; Drasdo, D.; Hengstler, J.G.; Schwarz, M. Phenotype and growth behavior of residual beta-catenin-positive hepatocytes in livers of beta-catenin-deficient mice. Histochem. Cell Biol., 2010, 134, 469-481.
56. Sekine, S.; Ogawa, R.; Kanai, Y. Hepatomas with activating Ctnnb1 mutations in 'Ctnnb1-deficient' livers: A tricky aspect of a conditional knockout mouse model. Carcinogenesis, 2011, 32, 622-628.
57. Zhang, X.F.; Tan, X.; Zeng, G.; Misse, A.; Singh, S.; Kim, Y.; Klaunig, J.E.; Monga, S.P. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: Role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology, 2010, 52, 954-965.
58. Kipp, A.; Banning, A.; Brigelius-Flohe, R. Activation of the glutathione peroxidase 2 (GPx2) promoter by beta-catenin. Biol. Chem., 2007, 388, 1027-1033. (Pubitemid 47584311)
59. Tan, X.; Yuan, Y.; Zeng, G.; Apte, U.; Thompson, M.D.; Cieply, B.; Stolz, D.B.; Michalopoulos, G.K.; Kaestner, K.H.; Monga, S.P. Beta-catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival during mouse development. Hepatology, 2008, 47, 1667-1679. (Pubitemid 351702749)
60. Decaens, T.; Godard, C.; de Reynies, A.; Rickman, D.S.; Tronche, F.; Couty, J.P.; Perret, C.; Colnot, S. Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology, 2008, 47, 247-258. (Pubitemid 351171062)
61. Aoki, K.; Taketo, M.M. Adenomatous polyposis coli (APC): A multi-functional tumor suppressor gene. J. Cell Sci., 2007, 120, 3327-3335. (Pubitemid 350028340)
62. Nejak-Bowen, K.; Monga, S.P. Wnt/beta-catenin signaling in hepatic organogenesis. Organogenesis, 2008, 4, 92-99.
63. Smith, G.; Henderson, C.J.; Parker, M.G.; White, R.; Bars, R.G.; Wolf, C.R. 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene, an extremely potent modulator of mouse hepatic cytochrome P-450 gene expression. Biochem. J., 1993, 289, 807-813. (Pubitemid 23074968)
64. Poland, A.; Mak, I.; Glover, E.; Boatman, R.J.; Ebetino, F.H.; Kende, A.S. 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene, a potent phenobarbital-like inducer of microsomal monooxygenase activity. Mol. Pharmacol., 1980, 18, 571-580. (Pubitemid 11205391)
65. Kelley, M.; Lambert, I.; Merrill, J.; Safe, S. 1,4-Bis[2-(3,5- dichloropyridyloxy)]benzene (TCPOBOP) and related compounds as inducers of hepatic monooxygenases. Structure-Activity effects. Biochem. Pharmacol., 1985, 34, 3489-3494. (Pubitemid 16252526)
66. Kress, S.; Konig, J.; Schweizer, J.; Loehrke, H.; Bauer-Hofmann, R.; Schwarz, M. p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Mol. Carcinogenesis, 1992, 6, 148-158.
67. Loeppen, S.; Koehle, C.; Buchmann, A.; Schwarz, M. A betacatenin- dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis, 2005, 26, 239-248. (Pubitemid 40207719)
68. Roose, J.; Clevers, H. TCF transcription factors: Molecular switches in carcinogenesis. Biochim. Biophys. Acta, 1999, 1424, M23-37. (Pubitemid 29488713)
69. Lustig, B.; Jerchow, B.; Sachs, M.; Weiler, S.; Pietsch, T.; Karsten, U.; van de Wetering, M.; Clevers, H.; Schlag, P.M.; Birchmeier, W.; Behrens, J. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol. Cell. Biol., 2002, 22, 1184-1193. (Pubitemid 34094854)
70. Yamamoto, Y.; Sakamoto, M.; Fujii, G.; Tsuiji, H.; Kenetaka, K.; Asaka, M.; Hirohashi, S. Overexpression of orphan G-proteincoupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology, 2003, 37, 528-533. (Pubitemid 36258773)
71. Haarmann-Stemmann, T.; Abel, J. The arylhydrocarbon receptor repressor (AhRR): Structure, expression, and function. Biol. Chem., 2006, 387, 1195-1199. (Pubitemid 44402065)
72. Abel, J.; Haarmann-Stemmann, T. An introduction to the molecular basics of aryl hydrocarbon receptor biology. Biol. Chem., 2010, 391, 1235-1248.
73. Bock, K.W. Aryl hydrocarbon or dioxin receptor: Biologic and toxic responses. Rev. Physiol. Biochem. Pharmacol., 1994, 125, 1-42. (Pubitemid 2124701)
74. Kawajiri, K.; Kobayashi, Y.; Ohtake, F.; Ikuta, T.; Matsushima, Y.; Mimura, J.; Pettersson, S.; Pollenz, R.S.; Sakaki, T.; Hirokawa, T.; Akiyama, T.; Kurosumi, M.; Poellinger, L.; Kato, S.; Fujii-Kuriyama, Y. Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc. Natl. Acad. Sci. USA, 2009, 106, 13481-13486.
75. Mathew, L.K.; Simonich, M.T.; Tanguay, R.L. AHR-dependent misregulation of Wnt signaling disrupts tissue regeneration. Biochem. Pharmacol., 2009, 77, 498-507.
76. Mathew, L.K.; Sengupta, S.S.; Ladu, J.; Andreasen, E.A.; Tanguay, R.L. Crosstalk between AHR and Wnt signaling through RSpondin1 impairs tissue regeneration in zebrafish. Faseb J., 2008, 22, 3087-3096.
77. Chesire, D.R.; Dunn, T.A.; Ewing, C.M.; Luo, J.; Isaacs, W.B. Identification of aryl hydrocarbon receptor as a putative Wnt/betacatenin pathway target gene in prostate cancer cells. Cancer Res., 2004, 64, 2523-2533. (Pubitemid 38523909)
78. Braeuning, A.; Buchmann, A. The glycogen synthase kinase inhibitor SB216763 is a partial agonist of the aryl hydrocarbon receptor. Drug Metab. Dispos., 2009, 37, 1576-1580.
79. Lindros, K.O.; Oinonen, T.; Johansson, I.; Ingelman-Sundberg, M. Selective centrilobular expression of the aryl hydrocarbon receptor in rat liver. J. Pharmacol. Exp. Ther., 1997, 280, 506-511. (Pubitemid 27171441)
80. Braeuning, A.; Ittrich, C.; Kohle, C.; Hailfinger, S.; Bonin, M.; Buchmann, A.; Schwarz, M. Differential gene expression in periportal and perivenous mouse hepatocytes. Febs J., 2006, 273, 5051-5061. (Pubitemid 44673296)
81. Sekine, S.; Gutierrez, P.J.; Lan, B.Y.; Feng, S.; Hebrok, M. Liverspecific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy. Hepatology, 2007, 45, 361-368. (Pubitemid 46374592)
82. Wolf, C.R.; Moll, E.; Friedberg, T.; Oesch, F.; Buchmann, A.; Kuhlmann, W.D.; Kunz, H.W. Characterization, localization and regulation of a novel phenobarbital-inducible form of cytochrome P450, compared with three further P450-isoenzymes, NADPH P450-reductase, glutathione transferases and microsomal epoxide hydrolase. Carcinogenesis, 1984, 5, 993-1001. (Pubitemid 14061248)
83. Wolf, C.R.; Buchmann, A.; Friedberg, T.; Moll, E.; Kuhlmann, W.D.; Kunz, H.W.; Oesch, F. Dynamics of the localization of drug metabolizing enzymes in tissues and cells. Biochem. Soc. Trans., 1984, 12, 60-62.
84. Mulholland, D.J.; Dedhar, S.; Coetzee, G.A.; Nelson, C.C. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr. Rev., 2005, 26, 898-915. (Pubitemid 41770157)
85. Pollenz, R.S. The aryl-hydrocarbon receptor, but not the arylhydrocarbon receptor nuclear translocator protein, is rapidly depleted in hepatic and nonhepatic culture cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol. Pharmacol., 1996, 49, 391-398.
86. Swales, K.; Negishi, M. CAR, driving into the future. Mol. Endocrinol., 2004, 18, 1589-1598.
87. Qatanani, M.; Moore, D.D. CAR, the continuously advancing receptor, in drug metabolism and disease. Curr. Drug Metab., 2005, 6, 329-339. (Pubitemid 41086766)
88. Braeuning, A., Heubach, Y., Knorpp, T., Kowalik, M.A., Templin, M., Columbano, A., Schwarz, M. Gender-specific interplay of signaling through β-catenin and CAR in the regulation of xenobioticinduced hepatocyte proliferation. Toxicol. Sci., 2011, 123, 113-122.
89. Whysner, J.; Ross, P.M.; Williams, G.M. Phenobarbital mechanistic data and risk assessment: Enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther., 1996, 71, 153-191. (Pubitemid 26323295)
90. Koike, C.; Moore, R.; Negishi, M. Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol. Pharmacol., 2007, 71, 1217-1221. (Pubitemid 46658675)
91. Braeuning, A.; Menzel, M.; Kleinschnitz, E.M.; Harada, N.; Tamai, Y.; Kohle, C.; Buchmann, A.; Schwarz, M. Serum components and activated Ha-ras antagonize expression of perivenous marker genes stimulated by beta-catenin signaling in mouse hepatocytes. Febs J., 2007, 274, 4766-4777. (Pubitemid 47353126)
92. Keyse, S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev., 2008, 27, 253-261.
93. Bluthgen, N.; Legewie, S.; Kielbasa, S.M.; Schramme, A.; Tchernitsa, O.; Keil, J.; Solf, A.; Vingron, M.; Schafer, R.; Herzel, H.; Sers, C. A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts. Febs J., 2009, 276, 1024-1035.
94. Simeckova, P.; Vondracek, J.; Prochazkova, J.; Kozubik, A.; Krcmar, P.; Machala, M. 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) induces degradation of adherens junction proteins and inhibits beta-catenin-dependent transcription in liver epithelial cells. Toxicology, 2009, 260, 104-111.
95. Knight, T.R.; Choudhuri, S.; Klaassen, C.D. Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers. Toxicol. Sci., 2008, 106, 329-338.
96. McCarthy, D.J.; Lindamood, C.; Hill, D.L. Effects of retinoids on metabolizing enzymes and on binding of benzo(a)pyrene to rat tissue DNA. Cancer Res., 1987, 47, 5014-5020. (Pubitemid 17146465)
97. Gad, M.Z. The distribution of non-specific carboxylesterases and glutathione S-transferases in different rat liver cells. Effects of vitamin A deficiency. Biochem. Pharmacol., 1994, 48, 139-144.
98. Kulkarni, A.A.; Kulkarni, A.P. Retinoids inhibit mammalian glutathione transferases. Cancer Lett., 1995, 91, 185-189.
99. Dai, G.; Chou, N.; He, L.; Gyamfi, M.A.; Mendy, A.J.; Slitt, A.L.; Klaassen, C.D.; Wan, Y.J. Retinoid X receptor alpha Regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol. Pharmacol., 2005, 68, 1590-1596. (Pubitemid 41654343)
100. Wu, Y.; Zhang, X.; Bardag-Gorce, F.; Robel, R.C.; Aguilo, J.; Chen, L.; Zeng, Y.; Hwang, K.; French, S.W.; Lu, S.C.; Wan, Y.J. Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxification processes in mouse liver. Mol. Pharmacol., 2004, 65, 550-557. (Pubitemid 38264022)
101. Volate, S.R.; Muga, S.J.; Issa, A.Y.; Nitcheva, D.; Smith, T.; Wargovich, M.J. Epigenetic modulation of the retinoid X receptor alpha by green tea in the azoxymethane-Apc Min/+ mouse model of intestinal cancer. Mol. Carcinog., 2009, 48, 920-933.
102. Xiao, H.; Hao, X.; Simi, B.; Ju, J.; Jiang, H.; Reddy, B.S.; Yang, C.S. Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats. Carcinogenesis, 2008, 29, 113-119. (Pubitemid 351201749)
103. Easwaran, V.; Pishvaian, M.; Salimuddin; Byers, S. Crossregulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr. Biol., 1999, 9, 1415-1418.
104. Xiao, J.H.; Ghosn, C.; Hinchman, C.; Forbes, C.; Wang, J.; Snider, N.; Cordrey, A.; Zhao, Y.; Chandraratna, R.A. Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J. Biol. Chem., 2003, 278, 29954-29962. (Pubitemid 36962384)
105. Zhang, D.D. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev., 2006, 38, 769-789. (Pubitemid 44903268)
106. Klaassen, C.D.; Reisman, S.A. Nrf2 the rescue: Effects of the antioxidative/electrophilic response on the liver. Toxicol. Appl. Pharmacol., 2010, 244, 57-65.
107. Chanas, S.A.; Jiang, Q.; McMahon, M.; McWalter, G.K.; McLellan, L.I.; Elcombe, C.R.; Henderson, C.J.; Wolf, C.R.; Moffat, G.J.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem. J., 2002, 365, 405-416. (Pubitemid 36135312)
108. Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; Igarashi, K.; Engel, J.D.; Yamamoto, M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the aminoterminal Neh2 domain. Genes Dev., 1999, 13, 76-86. (Pubitemid 29045117)
109. Jain, A.K.; Jaiswal, A.K. GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J. Biol. Chem., 2007, 282, 16502-16510. (Pubitemid 47100395)
110. Salazar, M.; Rojo, A.I.; Velasco, D.; de Sagarra, R.M.; Cuadrado, A. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J. Biol. Chem., 2006, 281, 14841-14851. (Pubitemid 43855189)
111. Forde, J.E.; Dale, T.C. Glycogen synthase kinase 3: A key regulator of cellular fate. Cell. Mol. Life Sci., 2007, 64, 1930-1944. (Pubitemid 47094432)
112. Eloranta, J.J.; Kullak-Ublick, G.A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys., 2005, 433, 397-412. (Pubitemid 39592794)
113. Borlak, J.; Dangers, M.; Thum, T. Aroclor 1254 modulates gene expression of nuclear transcription factors: Implications for albumin gene transcription and protein synthesis in rat hepatocyte cultures. Toxicol. Appl. Pharmacol., 2002, 181, 79-88. (Pubitemid 34625938)
114. Li, T.; Chiang, J.Y. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab. Dispos., 2006, 34, 756-764.
115. Cattin, A.L.; Le Beyec, J.; Barreau, F.; Saint-Just, S.; Houllier, A.; Gonzalez, F.J.; Robine, S.; Pincon-Raymond, M.; Cardot, P.; Lacasa, M.; Ribeiro, A. Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium. Mol. Cell. Biol., 2009, 29, 6294-6308.
116. Lindros, K.O.; Oinonen, T.; Issakainen, J.; Nagy, P.; Thorgeirsson, S.S. Zonal distribution of transcripts of four hepatic transcription factors in the mature rat liver. Cell Biol. Toxicol., 1997, 13, 257-262. (Pubitemid 27373396)